| Literature DB >> 33858542 |
Owen Stafford1, Anna Berry1,2, Laura K Taylor1,3, Sinead Wearen1, Cian Prendergast1, Eddie Murphy1,2, Mark Shevlin4, Louise McHugh1, Alan Carr1, Tom Burke5.
Abstract
OBJECTIVE: The unprecedented occurrence of a global pandemic is accompanied by both physical and psychological burdens that may impair quality of life. Research relating to COVID-19 aims to determine the effects of the pandemic on vulnerable populations who are at high risk of developing negative health or psychosocial outcomes. Having an ongoing medical condition during a pandemic may lead to greater psychological distress. Increased psychological distress may be due to preventative public health measures (e.g. lockdown), having an ongoing medical condition, or a combination of these factors.Entities:
Keywords: COVID-19; Comorbidity; Ireland; mental health; pandemic
Mesh:
Year: 2021 PMID: 33858542 PMCID: PMC8144807 DOI: 10.1017/ipm.2021.37
Source DB: PubMed Journal: Ir J Psychol Med ISSN: 0790-9667
MANOVA results for the DASS-21 and BIPQ
| Variable | Group | N | M | SD | F | p |
|
|---|---|---|---|---|---|---|---|
|
| |||||||
| Depression | Medical | 113 | 11.27 | 3.43 | 0.51 | 0.48 | 0.002 |
| Control | 116 | 10.95 | 3.46 | ||||
| Anxiety | Medical | 113 | 10.26 | 2.89 | 8.48* | 0.004 | 0.04 |
| Control | 116 | 9.22 | 2.52 | ||||
| Stress | Medical | 113 | 13.12 | 3.67 | 1.55 | 0.21 | 0.005 |
| Control | 116 | 12.59 | 3.67 | ||||
|
| |||||||
| Item 1 ( | Medical | 128 | 6.88 | 1.97 | 0.08 | 0.79 | 0 |
| Control | 125 | 6.95 | 2.06 | ||||
| Item 2 | Medical | 128 | 6.65 | 1.53 | 1.38 | 0.24 | 0.005 |
| Control | 125 | 6.42 | 1.51 | ||||
| Item 3 | Medical | 128 | 5.01 | 2.09 | 1.61 | 0.21 | 0.006 |
| Control | 125 | 5.36 | 2.32 | ||||
| Item 4 | Medical | 128 | 4.13 | 2.08 | 2.15 | 0.14 | 0.008 |
| Control | 125 | 4.52 | 2.21 | ||||
| Item 5 | Medical | 128 | 7.77 | 1.71 | 6.76** | 0.01 | 0.026 |
| Control | 125 | 7.15 | 2.08 | ||||
| Item 6 | Medical | 128 | 8.9 | 1.68 | 0.43 | 0.51 | 0.002 |
| Control | 125 | 8.76 | 1.66 | ||||
| Item 7 | Medical | 128 | 7.55 | 2.11 | 4.67** | 0.03 | 0.018 |
| Control | 125 | 6.96 | 2.27 |
ηp2, partial eta squared. Item brackets (e.g. consequences) refer to each dimension of illness perception the BIPQ assesses.
* p < .01, ** p < .05.
Multiple regression model predicting DASS-21 anxiety scores
| Group | R2 | Adj R2 | β | B | SE | p | CI 95% (B) | |
|---|---|---|---|---|---|---|---|---|
| Model | Medical Control | .154*** | .131*** | |||||
| BIPQ Q5 | Medical | −.02 | −.03 | .18 | .86 | −.39/.33 | ||
| Control | .06 | .08 | .15 | .58 | −.22//.39 | |||
| BIPQ Q7 | Medical | .29** | .42 | .16 | .008 | .11/.73 | ||
| Control | .16 | .23 | .16 | .14 | −.08/.54 | |||
| WEMWBS | Medical | −.24** | −.09 | .03 | .009 | −.16/−.02 | ||
| Control | −.22* | −.07 | .03 | .02 | −.14/−.01 |
R2, R-squared; Adj. R2, Adjusted R-squared; β, standardised beta value; B, unstandardised beta value; SE, Standard errors of B; CI 95% (B), 95% confidence interval for B; n = 398; Statistical significance: *p < .05; **p < .01; ***p < .001.